2016! Remove chairman, president , restructured the board, closed investigation, progress Amgen contract, phase out PFS line ( appears to indicated contracts were not profitable, plant up for sale,reduct workforce by 50% introduce new handheld injector.
3 contracts with large pharma still progressing well. Other potential pharma's had or have reservations about execution capabilities. Ryan and team addressing.
Pursuing other customers Radigan and Ian. Who unknown??
Clinical testing in Nov. announce company very pleased with results.
Company stating they have the best wearable technology. 3 steps vs other device suppliers with a 9 step process which is complexity in the world of focus on simplicity.
Cost structure down. Ryan playing it close to the vest. No AS over promising.
Value of the PFS contracts and patents unknown. Ryan charged with renegotiating contracts if possible.
Nothing said on Novartis program or Ocuject or AbbVie? Hidden value or hidden expense to resolve.
$26 million write down in 2016. Clear sailing in 2017 and beyond.
Still hiring. Happy holidays to all.
